HIV/AIDS Topics UCSF/amfAR HIV Cure Summit Reviews Progress in Cure-Related Research
- Details
- Category: Search for a Cure
- Published on Wednesday, 21 December 2016 00:00
- Written by Liz Highleyman
Researchers at the amfAR Institute for HIV Cure Research at the University of California at San Francisco (UCSF) presented an update on their latest cure-related work at a World AIDS Day summit on December 1. This multidisciplinary effort aims to understand HIV reservoirs within the body and ultimately to control or eliminate the virus.
Advocates Call for More Research on Immune-Enhancing Therapies for People with HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by HIVandHepatitis.com
HIV/AIDS activists recently issued a call for expanded research to accelerate the development of immune-enhancing therapies for HIV-positive immunological non-responders -- people who achieve viral suppression on antiretroviral therapy but do not see their CD4 T-cell count return to near-normal levels, and therefore remain at increased risk of illness and death.
HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Keith Alcorn
A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus 2 NRTIs for treatment-experienced HIV patients, according to a report at the International Congress on Drug Therapy in HIV Infection last month in Glasgow.
World AIDS Day: 18 Million Now on HIV Treatment but Many Still Lack Access
- Details
- Category: HIV Treatment
- Published on Tuesday, 29 November 2016 00:00
- Written by HIVandHepatitis.com
Thursday, December 1, is World AIDS Day, an opportunity to remember those lost to the epidemic and to focus on the continuing challenges of universal HIV prevention and treatment. According to a new report from UNAIDS, approximately 37 million people are living with HIV worldwide -- of whom more than 18 million are receiving antiretroviral therapy -- and there were about 2 million new infections in 2015.
HIV Glasgow: Darunavir/Ritonavir + Lamivudine Matches Triple-Drug HIV Therapy
- Details
- Category: Approved HIV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Keith Alcorn
Simplifying antiretroviral therapy to a 2-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a 3-drug regimen in people with suppressed viral load, Spanish investigators reported at the International Congress on Drug Therapy in HIV infection (HIV Glasgow) last month in Glasgow.
HIV Glasgow: 4-Days-On-3-Days-Off HIV Treatment Controls Viral Load in Pilot Study
- Details
- Category: HIV Treatment
- Published on Monday, 14 November 2016 00:00
- Written by Keith Alcorn
An experimental "4 days on, 3 days off" antiretroviral regimen kept viral load fully suppressed in 96% of people for 48 weeks in a French study presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. The study recruited people whose viral load had been fully suppressed on standard treatment for a median of 4 years, not people who had started therapy recently.
IDWeek 2016: Tenofovir Alafenamide Works Well and Improves Kidney and Bone Markers in Older HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
A coformulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older individuals, and was associated with improvements in kidney function and bone density, which may be of greater concern for this group, according to a presentation last week at IDWeek 2106 in New Orleans.
More Articles...
- IDWeek 2016: Omega-3 Fatty Acids May Improve Triglycerides and Inflammation in HIV+ People
- Coverage of IDWeek 2016
- Coverage of HIV Drug Therapy Glasgow 2016
- IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women
- HIV Glasgow: Dolutegravir and Central Nervous System Side-Effects -- Abacavir, Older Age Increase the Risk
Web Design and Development by